The introduction of biologic agents, specifically tumor necrosis factor inhibitors, has changed the face of disease-modifying therapy in rheumatoid arthritis (RA). As beneficial as these agents have been for many patients, not all individuals respond, with 30-40 percent having a sub-optimal clinical course and few experiencing a complete remission. This program will address the issues associated with TNF failure, outline strategies for enhancing TNF therapy and discuss possible alternatives that may be available.
An Internet-based, CME-certified professional education program. Estimated time to complete this educational activity: 1 hour.
Date of Release and Expiration
This course expired on January 13, 2007. Credit is not available for this activity.
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
Dr. Clifton O. Bingham III has received grants and research support from Abbott, Alexion, Amgen, Arthritis Foundation, Bristol Myers Squibb, Centacor, Genentech, Merck, NIH and Regeneron. He has served as a consultant for Abbott, Amgen, Aventis, Merck, McNeil, Novartis, Regeneron and Procter and Gamble.
Dr. Mark Genovese has received grants and research support from Amgen, Centocor, Abbott, Biogen Idec, Genentech and Roche. He has served as a consultant for Amgen, Centocor, Abbott, Biogen, Genentech and Roche.
Dr. Kathryn Hobbs has no relevant financial interest or relationships from a commercial interest whose products or services are discussed in or pertain to the content of this educational activity.
Dr. Eric M. Ruderman has received grants and research support from Amgen, Abbott, Bristol Myers Squibb, Genentech, Biogen Idec and Centocor. He has served as a consultant for Amgen, Wyeth, Abbott, Bristol Myers Squibb and Genentech. Dr. Ruderman has also received honorarium from Amgen and Abbott.